New Safety Concerns Raised Over Impella vs. IABP in Cardiogenic Shock. May 5, 2025, on Medscape).
New Safety Concerns Raised Over Impella vs. IABP in Cardiogenic Shock. May 5, 2025, on Medscape).
May 5, 2025)
Source: Medscape Summary
1. Study Overview:
• A new propensity-matched analysis compared Impella vs. IABP (Intra-Aortic Balloon Pump) for patients in cardiogenic shock.
• Presented at the SCAI 2025 conference in Washington, D.C.
2. Key Findings (30-day outcomes):
• Higher mortality with Impella:
• 42.3% (Impella) vs. 29.6% (IABP)
• Hazard Ratio: 1.59 | P < 0.001
• More cardiac arrest:
• 33.9% (Impella) vs. 26.8% (IABP)
• Higher sepsis rates:
• 14.6% vs. 12.3% (P = 0.024)
3. No significant differences in:
• Acute kidney injury, stroke, GI bleeding, atrial fibrillation, or VT
4. Clinical Context:
• Both Impella and IABP are used for temporary mechanical circulatory support in cardiogenic shock, often after MI.
• Impella provides stronger hemodynamic support but uses a larger catheter, increasing risk of bleeding, infection, and vascular injury.
5. Expert Insight – Dr. Diljon Chahal:
• Past trials (IMPRESS, ISAR-SHOCK) showed no clear mortality benefit of Impella.
• New data suggests more support ≠ better outcomes if complications rise.
• Emphasized the need for careful patient selection and more randomized trials.
6. Bottom Line:
While Impella offers greater short-term support, this study highlights a potential trade-off between hemodynamic benefit and procedural risk. Until stronger evidence is available, device choice should be individualized, not assumed.
